Food and Drug Administration
Center for Biologics Evaluation and Research
Summary Minutes
192nd Vaccines and Related Biological Products Advisory Committee Meeting

May 28, 2026

Committee Members
(Voting)
Adam Berger, PhD
Anna Durbin, MD
Hayley Gans, MD
Flor M. Munoz-Rivas, MD MSc
Michael R. Nelson, MD, PhD+
Saad B. Omer, MBBS, MPH, PhD

Consumer Representative Member
(Non-Voting)**
Jay Portnoy, MD+

Industry Representative Member
(Non-Voting)***
Temi Folaranmi, MD, MPH, MPP

Alternate Industry Representative
(Non-Voting) ~
James Kollar, MD +

Temporary Members
(Voting)
Hana M. El Sahly, MD
Manisha (Mo) Patel, MD, MS, MBA
Stanley M. Perlman, MD, PhD (*Acting)
Eric J. Rubin, MD, PhD

Speakers and Guest Speakers
(in order of speaking)
Natalie J. Thornburg, PhD - CDC speaker
Amanda B Payne, PhD, MPH - CDC speaker
Bart Haagmans, PhD
Fatimah Dawood, MD - CDC responder

Industry Speaker
(in order of speaking)
Darin Edwards, PhD
Rituparna Das, MD, PhD
Kayvon Modjarrad, MD, PhD
Tonya Colpitts, PhD

FDA Participants
David C. Kaslow, MD
Jerry Weir, PhD (Presenter)
Carol D. Weiss, MD, PhD (Presenter)
Sudhakar Agnihothram, BPharm, PhD

Designated Federal Officer (DFO)
Cicely Reese, PharmD

+Not Attending
*Chairperson
**Consumer Representative Member
***Industry Representative Member
~Alternate Industry Representative

These summary minutes for the May 28, 2026, meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) were approved on the 17th of September 2026.

I certify that I participated in the May 28, 2026, meeting of the VRBPAC meeting and that these minutes accurately reflect what transpired.

/s/
Cicely Reese, PharmD, LCDR
USPHS, DFO

/s/
Stanley Perlman, MD
Acting Chairperson

Food and Drug Administration
Center for Biologics Evaluation and Research
Summary Minutes
192nd Vaccines and Related Biological Products Advisory Committee Meeting

May 28, 2026

On May 28, 2026, the 192nd meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened in open session to discuss and make recommendations on the selection of the 2026-2027 Formula for COVID-19 vaccines for use in the United States.

On May 28, 2026, at 8:30 a.m. Eastern Daylight Time (EDT), Dr. Stanley Perlman, Acting Chairperson, called the meeting to order. The DFO, Dr. Cicely Reese, made administrative remarks, conducted rollcall, invited the VRBPAC members and consultants to introduce themselves, and read the Conflict of Interest (COI) statement into the public record. There were no conflict-of-interest waivers issued under 18 U.S. Code Section 208 in connection with this meeting.

Dr. Jerry Weir, Director, Division of Viral Products, Office of Vaccines Research and Review, provided the Introduction to the VRBPAC Meeting Topics, followed by a brief Questions and Answers (Q&A).

Following Introductory Remarks, Center for Disease Control and Prevention (CDC), Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC), FDA speakers, as well as regulated industry speakers provided presentations entitled:

- CDC: Update on Current Epidemiology of COVID-19 and SARS-CoV-2 Variants: Natalie J. Thornburg, PhD
- CDC: Updates on COVID-19 Vaccine Effectiveness: Amanda B Payne, PhD, MPH
- TAG-CO-VAC May 2026 Recommendation on Antigen Composition of COVID-19 Vaccines: Bart Haagmans, PhD
- Moderna Presentation: SPIKEVAX and MNEXSPIKE COVID-19 Vaccines Update: Darin Edwards, PhD; Rituparna Das, MD, PhD
- Pfizer Presentation: COMIRNATY COVID-19 Vaccine Update: Kayvon Modjarrad, MD, PhD
- Sanofi Presentation: NUVAXOVID COVID-19 Vaccine Update: Tonya Colpitts, PhD
- FDA Presentation: FDA Considerations and Recommendation for COVID-19 Vaccine 2026-2027 Formula: Carol D. Weiss, MD, PhD

A 40-minute lunch break was held after the FDA presentation.

After the lunch break, Dr. Perlman convened the Open Public Hearing (OPH). Five registered speakers presented remarks during the OPH. The Chairperson closed the session.

Immediately following the OPH, an additional Q&A session was held for the CDC, Industry, and FDA Presenters.

Dr. Perlman began the general Committee Discussion of the topic. The discussion topic was read into the record:

Discussion Topic for the Committee: Please discuss circumstances that may warrant recommendation of a non-JN.1 lineage variant (e.g., BA.3.2) for COVID-19 vaccine use in the U.S.

After the discussion topic concluded, the Chairperson and DFO invited and led the Committee into the voting session.

Food and Drug Administration
Center for Biologics Evaluation and Research
Summary Minutes
192nd Vaccines and Related Biological Products Advisory Committee Meeting

May 28, 2026

The outcome of the voting questions is noted below:

Voting Question 1: For the 2026-2027 Formula of COVID-19 vaccines in the U.S., does the committee recommend JN.1-lineage XFG variant as the preferred variant for an updated monovalent vaccine?

The vote was Yes: 8 No: 0 Abstain: 1.

Meeting Summary:

The 192nd VRBPAC meeting was held on 28 May 2026, to discuss and make recommendations on the selection of the 2026-2027 Formula for COVID-19 vaccines for use in the United States. The Committee voted 8–0 with one abstention to recommend the JN.1-lineage XFG variant as the preferred antigen for a monovalent 2026–2027 Formula for U.S-licensed COVID-19 vaccines. In the subsequent discussion, members raised concerns about declining genomic and wastewater surveillance capacity, the need for more frequent VRBPAC meetings to better align with COVID-19's biphasic seasonality, the importance of monitoring BA.3.2 for increased transmissibility or fitness, and the need for better age-stratified epidemiological data and challenge study data to establish protective antibody thresholds.

Following Committee voting and the summary, Acting Chairperson, Dr. Stanley Perlman, invited Dr. David C. Kaslow to provide closing remarks. Dr. Kaslow thanked the committee for the 192nd VRBPAC meeting, which discussed the selection of the 2026-2027 Formula for COVID-19 vaccines for use in the United States.

Following Dr. Kaslow's closing remarks, the committee DFO adjourned the meeting on May 28, 2026, at 3:00 p.m. EDT.

Additional meeting information and details may be obtained from the transcript, which may be viewed at:
2026 Meeting Materials, Vaccines and Related Biological Products Advisory Committee | FDA.

The recording of the webcast of the meeting may be viewed at:
https://youtube.com/live/3wU0NWzXvZY.